Artidis

Artidis is pioneering the integration of mechanobiology into clinical oncology diagnostics. Its core platform utilizes Atomic Force Microscopy (AFM) to quantify the physical properties of tumor cells within their native microenvironment, generating predictive biomarkers for metastatic risk and therapy response. The company is currently in the clinical investigation stage, with its technology positioned to augment standard pathology by providing same-day, actionable insights to guide chemotherapy sequencing, targeted therapies, and immunotherapy. Based in Basel, Switzerland, Artidis is a private, pre-revenue company advancing its platform through research collaborations and clinical studies.

Proprietary platform using Atomic Force Microscopy (AFM) to perform nanomechanical phenotyping of tumor biopsy samples. Measures physical properties (stiffness, viscosity, adhesion) of cancer cells within their native microenvironment to generate predictive biomarkers for metastatic potential and treatment response.

Artidis faces limited direct competition as a pioneer in clinical mechanobiology. Indirect competitors include companies offering genomic (e.g., Foundation Medicine, Guardant Health) or proteomic-based prognostic/predictive tests. Its unique value proposition is the measurement of physical properties, a dimension not addressed by current market leaders. However, if the field gains traction, large medtech or diagnostics firms with AFM expertise could become future competitors.